Patent US10753935

providing a test sample comprising a biological sample from a subject;

contacting the test sample with a HER2/CB2 heteromer binding composition comprising one or more antibodies that specifically bind to a HER2/CB2 heteromer, wherein the one or more antibodies comprise anti-HER2 antibodies, anti-CB2 antibodies, or both, or one or more antigen-binding fragments of the one or more antibodies to form a mixture;

incubating the mixture for a time sufficient to permit binding;

determining from the mixture a level of HER2/CB2 heteromer in the biological sample;

comparing the level of HER2/CB2 heteromer in the biological sample to a standard level of HER2/CB2 heteromer obtained from normal or cancer-free tissue or from an archived pathology sample containing a known level of HER2/CB2 heteromer protein expression;

classifying the level of HER2/CB2 heteromer in the biological sample as not detectable, low, or elevated based on the comparison; and

treating the subject classified as having an elevated level of HER2/CB2 heteromer by administering a pharmaceutical agent capable of disrupting a HER2/CB2 heteromer, wherein the pharmaceutical agent capable of disrupting the HER2/CB2 heteromer is Δ9-tetrahydrocannabinol.